New hope for brain cancer patients as scientists test drug to boost radiation
NCT ID NCT04216329
Summary
This early-stage trial is testing whether adding a new oral drug called selinexor to the standard treatment of radiation and chemotherapy (temozolomide) is safe for people newly diagnosed with glioblastoma, a fast-growing brain cancer. The main goal is to find the highest dose of selinexor that patients can tolerate without severe side effects. The study involves adults who have not yet received any chemotherapy or radiation for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.